| Expression pattern: |
DN |
| Associated gene: |
FOXP2, MET, AKT, mTOR |
| Associated microRNA: |
miR-300 |
| Biological function: |
Inhibits proliferation and metastasis; promotes apoptosis and autophagy; suppresses tumor growth and lung metastasis in vivo |
| Molecular mechanism: |
Acts as a miRNA sponge for miR-300 to upregulate FOXP2; FOXP2 transcriptionally inhibits MET, reducing AKT/mTOR signaling and regulating autophagy |
| Biological pathway or process: |
autophagy (promotes); apoptosis (promotes); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); EMT (inhibits); PI3K/AKT/mTOR (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
S
|
| Validation methods: |
circRNA-seq; RT-qPCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; Back-Splice Junction PCR / divergent primers PCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Survival Analysis; Transfection; CCK8; Colony Formation Assay; EdU Staining; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; RNA Pull-Down; Luciferase Reporter Assay; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining; ChIP / ChIP-seq |
| Clinical significance: |
Lower expression of circST3GAL6 was associated with worse overall survival; circST3GAL6 expression was negatively correlated with tumour stage and size |
| Description: |
circST3GAL6 is down-regulated in gastric cancer and functions as a tumor suppressor. It sponges miR-300 to increase FOXP2, which transcriptionally represses MET and dampens AKT/mTOR signaling, thereby promoting autophagy and apoptosis and inhibiting proliferation and metastasis in vitro and in vivo. |
| Confidence score: |
0.8849 |